ARTICLE | Financial News
Harbour BioMed raises $85M series B on heels of cancer deals
August 31, 2018 6:21 PM UTC
Immuno-oncology company Harbour BioMed (Shanghai, China) raised $85 million in a series B round led by GIC. New investors China Life Private Equity Investment Company and Vertex Ventures also participated as did existing investors AdvanTech and Legend Capital.
In August, Harbour gained rights to develop cancer programs from Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. and India’s Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296). Kelun-Biotech granted Harbour exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region, while Glenmark granted Harbour Greater China rights to develop and commercialize GBR 1302, a bispecific mAb that binds CD3 and HER2...